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Oral melanoma accounts for approximately 1% of
all melanomas.1 In contrast to cutaneous melanoma,
the risk factors for development of oral melanoma
are largely unknown. Immunosuppressive states,
including HIV infection and iatrogenic immunosup-
pression, are associated with an increased risk of
melanoma development.2 Pregnancy has not been
found to impact melanoma progression or overall
survival.3 We present a case of oral melanoma in a
pregnant, HIV-positive woman to emphasize the
need for prompt evaluation of evolving pigmented
lesions during times of immunosuppression and
physiologic change.
CASE REPORT
A 30-year-old gravid, African-American woman
with multidrug-resistant HIV based on genotype
testing presented to the Department of Dermatology
with a 10-year history of asymptomatic hyperpigmen-
tation of the gingiva and lip, which had darkened over
the course of her current pregnancy. Physical exam-
ination found an asymmetric, ill-defined, 3-cm dark
brown and black plaque with irregular borders
involving the vermillion and mucosal lip, gingiva,
and hard palate (Fig 1). There was no cervical
adenopathy. Initial punch biopsy from the right upper
mucosal lip found a melanoma in situ involving the
lateral margins. Subsequent incisional biopsy found
invasive mucosal lentiginous melanoma with a
Breslow depth of 1.45mm (Fig 2). Pertinent laboratory
findings included a decreased CD4 count of 177 cells
per cubic millimeter and a viral load of 624 copies per
milliliter. After multidisciplinary consensuswith otolar-
yngology and surgical oncology, the patient under-
went wide resection with 1-cm margins after delivery.the Department of Dermatology, Eastern Virginia Medical
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u.Sentinel lymph nodebiopsy resultswere negative. The
patient is disease free 21 months after resection and
has required no further adjuvant treatment.DISCUSSION
Oral melanoma is a rare subtype of melanoma of
unknown etiology.4 There is weak evidence suggest-
ing possible association with tobacco use, chronic
inflammation, and inhaled environmental carcino-
gens.1 Approximately 30% of oral melanomas arise
from preexisting oral pigmentation; the remainder
are thought to arise de novo.1 Oral melanoma is more
prevalent in men and individuals of Japanese and
African descent and rarely occurs before the age of
30.1 Although oral melanoma most often presents
with irregular hyperpigmentation of the hard palate
and maxillary gingiva, a small portion (2.9%-5.0%)
are amelanotic.1,5 The differential diagnosis includes
postinflammatory hyperpigmentation, oral melan-
otic macules, physiologic pigmentation, medication-
induced hyperpigmentation (eg, antiretrovirals such
as azidothymidine), and Kaposi’s sarcoma.4
Unlike cutaneous melanoma, oral melanoma is
usually in the vertical growth phase at the time of
diagnosis.4 The low 5-year survival rate of 10%-25% is
likely caused by a combination of factors including
delays in detection and rich vascularity of the oral
mucosa facilitating distant metastasis.5 Patient age
greater than 55, lymph node metastasis, and diameter
greater than 4 cm are all associated with a worse
prognosis.5JAAD Case Reports 2015;1:120-2.
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Fig 1. Oral melanoma manifesting as an asymmetric, ill-
defined dark brown and black plaque with irregular
borders involving the vermillion and mucosal lip and
gingiva.
Fig 2. Invasive mucosal lentiginous melanoma. Breslow
depth of 1.45 mm. (Hematoxylin-eosin stain.)
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treatment of this rare condition. A commonly used
staging system for head and neck melanomas,
including oral melanoma, is of prognostic value
and recognizes 3 stages: stage I for localized disease,
stage II for lymph node metastasis, and stage III for
distant metastasis.5 Clinical staging at diagnosis is
found to be the most important predictor of
outcome.5 Computed tomography or magnetic reso-
nance imaging can be used to evaluate the primary
tumor site and cervical lymph nodes.1 Although
sentinel lymph node biopsy seems to be reliable
for cutaneous melanoma, the utility of this diagnostic
tool in oral melanoma requires further investigation.6
Metastatic workup, including lactate dehydrogenase,
chest radiograph, and positron emission tomogra-
phy of the chest, abdomen, and pelvis, is also
frequently used.1,5 The mainstay of treatment for
oral melanoma involves wide surgical resection with
appropriate margins. If anatomic complexities of the
oral cavity preclude acquisition of appropriate mar-
gins, more narrow margins are justified.1,4 Evidence
for the role of radiation and chemotherapy either
alone or as adjuvant therapy for advanced disease is
conflicting.7 Although some studies have found areduction in local recurrence and distant metastasis,
other studies have been unable to show improve-
ments in survival.5,7
Immunosuppression is a known risk factor for
cutaneous melanoma.8 Recipients of renal trans-
plants are approximately 3.6 times more likely to
get melanoma compared with individuals in the
general population.8 Moreover, immunosuppressed
patients with melanoma have increased mortality
rates, independent of Breslow depth, compared with
their immunocompetent counterparts.2 Similarly,
HIV/AIDS patients have a 50% increased risk of
melanoma and a significantly shorter survival time
compared with those without HIV/AIDS.2 One study
found that median overall survival for HIV-positive
patients was 2.8 years compared with 6.4 years in
HIV-negative patients.9 A recent meta-analysis
examining the effects of highly active antiretroviral
therapy (HAART) treatment on melanoma risk found
that patients with HIV/AIDS in the post-HAART era
possessed a comparable risk of melanoma as those
diagnosed during the pre-HAART era.2 These find-
ings suggest that there may be multiple pathways
linking HIV infection and melanoma, including im-
munodeficiency, chronic immune inflammation, and
immune dysfunction.2 To our knowledge, oral mel-
anoma in the setting of underlying HIV is exceed-
ingly rare with only one other case described in the
literature.10
Melanoma is one of the most common malig-
nancies diagnosed during pregnancy and accounts
for up to 25% of newly diagnosed cancers in
pregnant women.3 Pregnancy is associated with a
significant decrease in lymphocytes and suppres-
sion of T lymphocyte activity with diminished
interleukin and interferon secretion.3 It was initially
hypothesized that the relative immunosuppression
during pregnancy favored more aggressive mela-
noma progression.3 However, larger epidemiologic
studies have since found that pregnancy has no
significant impact on disease progression and over-
all melanoma-specific survival.3
This case is important for several reasons. First, it
adds to the body of evidence showing involvement
of the immune system in melanoma development.
Next, we speculate that the known risk factors for
melanoma may operate differently in the setting of
immunosuppression and within different subpopu-
lations including HIV-positive patients. Finally, this
case illustrates the importance of maintaining a high
level of suspicion for evolving pigmented lesions
irrespective of patient race or ethnicity, especially
during times of immune compromise. Vigilant sur-
veillance and education remain essential in all pa-
tient populations to maximize outcomes.
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